A list of clinical ...
 
Notifications
Clear all

A list of clinical trials for platinum-resistant recurrent ovarian cancer


Daniel
(@daniel)
Admin
Joined: 6 years ago
Posts: 1036
Topic starter  
From https://cdrjournal.com/article/view/3829

Clinical trials for platinum-resistant recurrent ovarian cancer

  Identifier Function Phase
Immune checkpoint inhibitor
   Durvalumab NCT03026062 Programmed cell death ligand 1 inhibitor   2
  NCT03699449     2
  NCT02431559     1/2
  NCT02764333     2
  NCT04019288     1/2
  NCT02963831     2
  NCT02811497     2
   Pembrolizumab NCT02608684 Targets programmed cell death protein 1 receptor   2
   Atezolizumab NCT03363867 Targets programmed cell death ligand 1 (PD-L1)   2
   TSR-042 NCT03574779 Anti-PD1 antibody   2
   Tremelimumab NCT02953457 Activates the immune system by targeting CTLA-4   2
  NCT03026062     2
   Ipilimumab NCT03508570 Activates the immune system by targeting CTLA-4   1
   Avelumab NCT02580058 Targets the protein programmed death-ligand 1 (PD-L1)   3
Anti-angiogenic inhibitor
   Apatinib NCT04348032 Vascular endothelial growth factor receptor-2 (VEGFR2) inhibitor   2
   Cediranib NCT03699449 Vascular endothelial growth factor inhibitor   2
   Anlotinib NCT04376073 c-MET/TIE-2/VEGFR inhibitor   2
   Tivozanib NCT01853644 Oral VEGF receptor tyrosine kinase inhibitor   2
   Bevacizumab NCT03093155 VEGF receptor tyrosine kinase inhibitor   2
   Sevacizumab NCT03763123 VEGF receptor tyrosine kinase inhibitor   1
   VB-111 NCT03398655 An anti-angiogenic gene therapy   3
   Regorafenib NCT02736305 Dual-targeted VEGFR2-TIE2 tyrosine kinase inhibition   2
   Pazopanib NCT01402271 Selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumor growth and inhibits angiogenesis   1/2
PARP inhibitor
   Olaparib NCT02889900 PARP inhibitor   2
  NCT04633239     1
  NCT03117933     2
  NCT02898207     1
  NCT03161132     2
  NCT03699449     2
  NCT03314740     2
  NCT02502266     2/3
   Niraparib NCT04376073 PARP inhibitor   2
  NCT03955471     2
  NCT04502602     1
  NCT03586661     1
  NCT04217798     2
  NCT03944902     1
  NCT01227941     1
   Rucaparib NCT03552471 PARP inhibitor   1
   Talazoparib NCT03330405 PARP inhibitor   2
Other tyrosine kinase inhibitor
   BAY1895344 NCT04267939 Ataxia-telangiectasia and Rad3 related protein (ATR) inhibitor   1
   Prexasertib NCT03414047 CHK1 inhibitor   2
   Adavosertib NCT03579316 WEE1 G2 checkpoint kinase (WEE1) inhibitor   2
   Copanlisib NCT03586661 Phosphatidylinositol-3-kinase (PI3K) inhibitor   1
   TP-0903 NCT02729298 Targets the AXL (derived from the Greek word “anexelekto”, meaning uncontrolled) receptor tyrosine kinase   1
   AVB-S6-500 NCT03639246 Targets the AXL (derived from the Greek word “anexelekto”, meaning uncontrolled) receptor tyrosine kinase   1/2
   Ixabepilone NCT03093155 Stabilizes microtubules   2
  NCT02595892     2
   Cobimetinib NCT03363867 MEK inhibitor   2
  NCT02101775     2
   Motolimod NCT02431559 Toll-like receptor 8 (TLR8) agonist   1/2
   Entinostat NCT03924245 Benzamide histone deacetylase inhibitor   1/2
This topic was modified 6 months ago by Daniel

Quote
Topic Tags
Share: